<DOC>
	<DOCNO>NCT02865733</DOCNO>
	<brief_summary>The aim study determine safety efficiency Remodulin®（Treprostinil Injection）to reduce pulmonary arterial pressure prevent pulmonary hypertension ( PH ) Fontan operation univentricular physiology .</brief_summary>
	<brief_title>Study Remodulin® Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery</brief_title>
	<detailed_description>PH significant contributor postoperative morbidity mortality congenital heart disease , especially Fontan operation univentricular physiology . Mild increase pulmonary vascular resistance may lead failure Fontan circulation . Remodulin® approve treatment adult PH , little known effect child PH Fontan operation . The study aim determine safety efficiency Remodulin® reduce pulmonary arterial pressure prevent PH child Fontan operation . Meanwhile pharmacokinetics drug check without peritoneal dialysis .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>After Fontan procedure , criterion meet 1. mPAP great 15 mmHg 2 . TPG great 6 mmHg ( exclude obstruction cavopulmonary anastomosis ) After Fontan surgery : 1 . Severe arrhythmia lead low cardiac output 2 . Platelets small 50,000*109/L obvious bleeding</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Remodulin®</keyword>
	<keyword>pulmonary vascular resistance</keyword>
	<keyword>univentricular physiology</keyword>
</DOC>